Hepatitis C following liver transplantation: Current approach and future research opportunities

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of review The treatment of hepatitis C virus infection (HCV) in liver transplant recipients was very limited until direct-acting antivirals became widely available. We review the current approach to HCV treatment following liver transplantation and future research opportunities. Recent findings Current treatment of HCV infection with all oral new direct-acting antivirals in the postliver transplant setting is easier, shorter, tolerable, and more effective with high-sustained virological response rates. However, some challenges remain, including the optimal timing of therapy, drug-drug interactions, renal insufficiency, and HIV coinfection. Summary Patients with recurrent HCV following liver transplant will significantly benefit from all oral new direct acting antivirals. Ongoing studies will determine the optimal timing and combination in this unique population.

Original languageEnglish (US)
Pages (from-to)346-352
Number of pages7
JournalCurrent opinion in infectious diseases
Volume29
Issue number4
DOIs
StatePublished - Aug 1 2016

Keywords

  • current treatment
  • hepatitis C
  • liver transplant

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Hepatitis C following liver transplantation: Current approach and future research opportunities'. Together they form a unique fingerprint.

Cite this